“Myasthenia Gravis - Pipeline Review, H1 2012”

Global Markets Direct's, 'Myasthenia Gravis - Pipeline Review, H1 2012', provides an overview of the Myasthenia Gravis therapeutic pipeline. This report provides information on the therapeutic development for Myasthenia Gravis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Myasthenia Gravis.

Scope

- A snapshot of the global therapeutic scenario for Myasthenia Gravis.

- A review of the Myasthenia Gravis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Myasthenia Gravis pipeline on the basis of route of administration and molecule type.

- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.

- Key discontinued pipeline projects.

- Latest news and deals relating to the products.

Reasons to Buy

- Identify and understand important and diverse types of therapeutics under development for Myasthenia Gravis.

- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.

- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.

- Devise corrective measures for pipeline projects by understanding Myasthenia Gravis pipeline depth and focus of Myasthenia Gravis therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

For more information visit http://www.researchandmarkets.com/research/2xb8xr/myasthenia_gravis

Source: Global Markets Direct